Individualized or Modified Chemotherapy (Dose Adjustment or Delay)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Source‎: Leuk Res 2011;35(8):991-7.

Indexed‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (opens new window)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (opens new window)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Source‎: Br J Haematol 2014;165(4):497-503.

Indexed‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (opens new window)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (opens new window)

Dainer PM, Knupp CL, Sartiano GP.

Source‎: Am J Hematol 1992;40(2):156-7.

Indexed‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (opens new window)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (opens new window)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Source‎: Lancet Oncol 2013;14(6):525-33.

Indexed‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (opens new window)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (opens new window)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Source‎: N Engl J Med 2020;383(7):617-29.

Indexed‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (opens new window)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (opens new window)

El Chaer F, Ballen KK

Source‎: Br J Haematol 2020;190(5):696-707.

Indexed‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (opens new window)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (opens new window)

Emadi A, Bade NA, Stevenson B, Singh Z.

Source‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Indexed‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (opens new window)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (opens new window)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Source‎: J Clin Oncol 2009;27(28):4733-40.

Indexed‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (opens new window)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (opens new window)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Source‎: Int J Hematol 1997;65(4):415-6.

Indexed‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (opens new window)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (opens new window)

Garelius H, Grund S, Stockelberg D.

Source‎: Clin Case Rep 2015;3(5):287-90.

Indexed‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (opens new window)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (opens new window)

Juliusson G.

Source‎: Am J Hematol 1996;53(1):49.

Indexed‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (opens new window)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (opens new window)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Source‎: Eur J Haematol 2004;72(4):264-7.

Indexed‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (opens new window)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (opens new window)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Source‎: Am J Hematol 1996;51(3):251-2.

Indexed‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (opens new window)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (opens new window)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Source‎: Hematol Oncol 2014;32(1):40-6.

Indexed‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (opens new window)

Cytarabine dose for acute myeloid leukemia. (opens new window)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Source‎: N Engl J Med 2011;364(11):1027-36.

Indexed‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (opens new window)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (opens new window)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Source‎: Bone Marrow Transplant 2003;32(4):433-6.

Indexed‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (opens new window)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (opens new window)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Source‎: N Engl J Med. 2022;386(16):1519-31.

Indexed‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (opens new window)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (opens new window)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Source‎: Gynecol Oncol 2012;124(2):221-4.

Indexed‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (opens new window)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (opens new window)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Source‎: Leuk Res Rep. 2022 25;18:100355.

Indexed‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (opens new window)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (opens new window)

Norfolk DR, Wade P, Carter R.

Source‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (opens new window)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opens new window)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Source‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexed‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opens new window)

Hematopoietic growth factors: personalization of risks and benefits. (opens new window)

Puhalla S, Bhattacharya S, Davidson NE.

Source‎: Mol Oncol 2012;6(2):237-41.

Indexed‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (opens new window)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (opens new window)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Source‎: Leuk Lymphoma 2021;62(6):1497-501.

Indexed‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (opens new window)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (opens new window)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Source‎: Blood 2020;135(7):463-71.

Indexed‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (opens new window)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (opens new window)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Source‎: Bone Marrow Transplant 2005;36(8):715-20.

Indexed‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (opens new window)

A Mexican way to cope with stem cell grafting. (opens new window)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Source‎: Hematology 2012;17 Suppl 1:S195-7.

Indexed‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (opens new window)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (opens new window)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Source‎: Blood 2009;113(9):1875-91.

Indexed‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (opens new window)

SCT in Jehovah's Witnesses: the bloodless transplant. (opens new window)

Sloan JM, Ballen K.

Source‎: Bone Marrow Transplant 2008;41(10):837-44.

Indexed‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (opens new window)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (opens new window)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Source‎: Cancer 2006;107(8):1839-43.

Indexed‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (opens new window)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (opens new window)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Source‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indexed‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (opens new window)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (opens new window)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Source‎: Onco Targets Ther 2013;7:13-21.

Indexed‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (opens new window)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (opens new window)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Source‎: J Clin Oncol 2007;25(30):4722-9.

Indexed‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (opens new window)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (opens new window)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Source‎: Blood 2020;135(24):2137-45.

Indexed‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (opens new window)